Overlooked cases of mild cognitive impairment: Implications to early Alzheimer's disease

Maamoon Mian1, Jihane Tahiri2, Ryan Eldin3

  • 1Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX 79430, USA.

PubMed

Insights

Mild cognitive impairment (MCI) and Alzheimer's disease (AD) impact the elderly. The Montreal Cognitive Assessment (MoCA) shows promise for early detection, outperforming the Mini-Mental State Examination (MMSE).

Area of Science:

  • Gerontology and Neurology
  • Cognitive Disorders Research

Background:

  • Mild cognitive impairment (MCI) represents an early stage of cognitive decline, distinct from healthy aging, impacting functions like memory, language, and spatial perception.
  • Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD) are progressive neurodegenerative conditions significantly affecting the elderly population.

Purpose of the Study:

  • To investigate the signs of MCI, early AD, and healthy brain aging.
  • To assess factors influencing cognitive disorder progression, pathology development, and susceptibility.
  • To compare diagnostic tools for early detection of cognitive impairment.

Main Methods:

  • A systematic literature review of over 100 articles was conducted.
  • Focus was placed on studies concerning MCI, AD, and ADRD in elderly populations.
  • Analysis included factors such as ethnicity, gender, lifestyle, comorbidities, and diagnostic efficacy.

Main Results:

  • Ethnicity influences MCI prevalence, with observed disparities among diverse populations.
  • Gender differences impact cognitive performance and decline rates.
  • Lifestyle factors and comorbidities significantly affect cognitive health.
  • The Montreal Cognitive Assessment (MoCA) demonstrates superior efficacy over the Mini-Mental State Examination (MMSE) for early MCI detection.

Conclusions:

  • Cognitive disorders are multifaceted, influenced by a complex interplay of demographic, lifestyle, and clinical factors.
  • Personalized management strategies are essential, considering ethnic and gender variations.
  • The MoCA is a more sensitive tool for identifying early-stage MCI, aiding timely intervention.

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
467
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
112
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
181
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
120